Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | SLC9A1 | P19634 | 4/20 | 0.43 |
| ▸ | TLR8 | Q9NR97 | 5/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CNR1 | P21554 | 1/20 | 0.38 |
| ▸ | CNR2 | P34972 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9872320 | 0.98 | CYP1A2 (0.53) | CYP1A2SLC9A1TLR8KMT2AMEN1 | |
| SCHEMBL1027818 | 0.98 | CYP1A2 (0.53) | CYP1A2SLC9A1TLR8KMT2AMEN1 | |
| SCHEMBL9871920 | 0.98 | CYP1A2 (0.53) | CYP1A2SLC9A1TLR8KMT2AMEN1 | |
| SCHEMBL9872492 | 0.98 | CYP1A2 (0.53) | CYP1A2SLC9A1TLR8KMT2AMEN1 | |
| SCHEMBL18496466 | 0.94 | CYP1A2 (0.57) | CYP1A2SLC9A1KMT2AMEN1HTT | |
| SCHEMBL21270136 | 0.89 | CYP1A2 (0.67) | CYP1A2KMT2AMEN1HTTLMNA | |
| SCHEMBL15323890 | 0.85 | — | — | |
| SCHEMBL21270138 | 0.84 | CYP1A2 (0.67) | CYP1A2KMT2AMEN1HTTLMNA | |
| SCHEMBL21270133 | 0.79 | CYP1A2 (0.73) | CYP1A2KMT2AHTTLMNA | |
| SCHEMBL2088514 | 0.79 | P2RX7 (0.46) | CYP1A2SLC9A1KMT2AMEN1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8980837-B2 | Inhibitors of IAP | GENENTECH, INC. (US) | 2015-03-17 | — | — | US | disclosed |
| US-8907092-B2 | Inhibitors of IAP | GENENTECH, INC. (US) | 2014-12-09 | — | — | US | disclosed |
| EP-1778718-B1 | INHIBITORS OF IAP | GENENTECH INC (US) | 2014-10-08 | — | — | EP | disclosed |
| US-20120202750-A1 | INHIBITORS OF IAP | GENENTECH, INC. (US) | 2012-08-09 | — | — | US | disclosed |
| US-8110568-B2 | Inhibitors of IAP | GENENTECH, INC. (US) | 2012-02-07 | — | — | US | disclosed |
| US-20110077265-A1 | INHIBITORS OF IAP | GENENTECH, INC. (US) | 2011-03-31 | — | — | US | disclosed |
| US-20110046066-A1 | INHIBITORS OF IAP | GENENTECH, INC. (US) | 2011-02-24 | — | — | US | disclosed |
| EP-2240506-A1 | INHIBITORS OF IAP | Genentech, Inc. (US) | 2010-10-20 | — | — | EP | disclosed |
| US-20100256115-A1 | INHIBITORS OF IAP | COHEN FREDERICK | 2010-10-07 | — | — | US | disclosed |
| EP-2184281-A1 | Phenyl-thiophene type vitamin D receptor modulators | Eli Lilly & Company (US) | 2010-05-12 | — | — | EP | disclosed |
| EP-1587905-A3 | VESICANT TREATMENT WITH PHENYL-THIOPHENE TYPE VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-12-14 | — | — | EP | disclosed |
| EP-1587905-A2 | VESICANT TREATMENT WITH PHENYL-THIOPHENE TYPE VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-10-26 | — | — | EP | disclosed |
| EP-1511740-A1 | PHENYL-THIOPHENE TYPE VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2005-03-09 | — | — | EP | disclosed |
| US-20040185539-A1 | Process for the preparation of 2-hydroxymethyl-pyrolidine 3, 4-diols | LONZA AG (CH) | 2004-09-23 | — | — | US | disclosed |
| WO-2004063348-A2 | VESICANT TREATMENT WITH PHENYL-THIOPHENE TYPE VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2004-07-29 | — | — | WO | disclosed |
| EP-1379676-A2 | PROCESS FOR THE PREPARATION OF 2-HYDROXYMETHYL-PYROLIDINE-3,4-DIOLS | LONZA AG (CH) | 2004-01-14 | — | — | EP | disclosed |
| WO-2003101978-A1 | PHENYL-THIOPHENE TYPE VITAMIN D RECEPTOR MODULATORS | ELI LILLY AND COMPANY (US) | 2003-12-11 | — | — | WO | disclosed |
| WO-2002074737-A2 | PROCESS FOR THE PREPARATION OF 2-HYDROXYMETHYL-PYROLIDINE-3,4-DIOLS | LONZA AG (CH) | 2002-09-26 | — | — | WO | disclosed |
| WO-1995014679-A1 | TETRAZOLE-SUBSTITUTED UREA ACAT INHIBITORS | PARKE, DAVIS & COMPANY (US) | 1995-06-01 | — | — | WO | disclosed |
| US-5362744-A | Treatnent of athrosclerosis, anticholesterol agents | WARNER-LAMBERT COMPANY (US) | 1994-11-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040185539-A1 | Process for the preparation of 2-hydroxymethyl-pyrolidine 3, 4-diols | HPD, DHPS, DPYD | CYP1A2 133/4885SLC9A1 3050/4885TLR8 3225/4885 |
| US-20110046066-A1 | INHIBITORS OF IAP | BIRC5, XIAP, BIRC3 | CYP1A2 4834/4885SLC9A1 3236/4885TLR8 4624/4885 |
| US-20120202750-A1 | INHIBITORS OF IAP | XIAP, BIRC5, BIRC3 | CYP1A2 4837/4885SLC9A1 3057/4885TLR8 4604/4885 |
| US-20100256115-A1 | INHIBITORS OF IAP | XIAP, BIRC5, BIRC3 | CYP1A2 4837/4885SLC9A1 3057/4885TLR8 4604/4885 |
| US-20110077265-A1 | INHIBITORS OF IAP | XIAP, BIRC5, BIRC2 | CYP1A2 4719/4885SLC9A1 4659/4885TLR8 4625/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.